If you’ve spent a lot of time outdoors in New England, you’ve likely crossed paths with, and probably stepped on, lichens.

Lipella Pharmaceuticals (LIPO) announced that its abstract on LP-10 for the treatment of Oral Lichen Planus, OLP, has been accepted for podium ...

Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine” ...

The post Lipella Reports Additional Positive Data from Phase 2a Trial of LP-310 in Oral Lichen Planus appeared first on PRISM MarketView.

Statistically significant improvements observed across clinical endpoints; final cohort results expected in Q2 2025 ...

Lipella Pharmaceuticals (LIPO) announced topline results from the second cohort of its Phase 2a multicenter, dose-ranging trial evaluating ...

Second Cohort Results Highlight Efficacy Across All Key Measures and Reinforce Safety of Twice-Daily Oral Rinse Phase 2a Study Now Fully Enrolled Across All Three Dose Cohorts Advancing Toward Phase ...

Moss and lichen may grow on solid, undisturbed surfaces, such as trees on your property. And though they aren't necessarily ...

Lipella Pharmaceuticals has concluded subject enrollment in its multicentre Phase IIa trial of liposomal tacrolimus oral rinse LP-310, which is aimed at treating oral lichen planus (OLP). The ...

“The completion of enrollment in our Phase 2a trial marks an important step in advancing a non-steroidal, locally delivered treatment for oral lichen planus, an underserved condition with no FDA ...

PITTSBURGH, April 08, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology ...